Partner with the Centre for Drug Development

We partner with academics, biotech and pharmaceutical companies worldwide to develop novel cancer treatments that might not otherwise make it to clinical trial.

As a partner, you can access our expertise in antibodies, cell therapies, vaccines, drug conjugates and small molecules. Our flexible business models allow for shared risk-reward partnerships. 

We take responsibility for all trial sponsor activities, helping complete preclinical packages, delivering regulatory submissions, clinical study management and ongoing medical support.

Get in touch

Our drug development expertise enables us to design, sponsor and deliver science-driven, first-in-human clinical trials. We partner globally to increase the number of new cancer treatments, advancing novel oncology agents into clinical development to maximise impact for cancer patients.  

Through these kinds of partnerships, we offer an alternative path for you to fully realise your oncology pipelines and develop promising anti-cancer agents they might otherwise be unable to bring to clinical trial. 

How do our clinical development partnerships work?

• You grant us a licence to undertake a clinical trial while retaining background intellectual property rights. 
• We design, set up and deliver first-in-human and early clinical development trials on a shared risk-reward basis through our Experimental Cancer Medicine Centres network. 
• You have the first option to license the clinical trial data, and partners can license results and intellectual property developed under the programme.